Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment

Launched by ASAN MEDICAL CENTER · Jul 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to monitor patients who have been treated for hepatocellular carcinoma (HCC), a type of liver cancer. After treatment, many patients worry about the cancer coming back. The trial aims to see if using a special type of MRI called abbreviated contrast-enhanced MRI, which uses a specific contrast agent called gadoxetic acid, is an effective and safer option for checking for any signs of cancer recurrence in patients who have been cancer-free for more than two years. This method could help reduce the risks associated with other imaging tests like CT scans, which involve radiation exposure.

To be eligible for the trial, participants must be over 20 years old and have been free of cancer for at least two years after their initial treatment. They should have no other active cancers, significant health issues, or conditions that would make an MRI difficult. If someone joins the study, they can expect to undergo the abbreviated MRI procedure as part of regular follow-up care, helping researchers understand if this method can be a reliable option for monitoring liver cancer recurrence. This could lead to safer and more efficient ways to keep track of patients' health after treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with more than two years without recurrence after curative treatment (surgery or local ablation) for HCC
• • 2. Patients with no history of systemic treatment, radiation therapy, or trans-arterial chemoembolization for HCC
• • 3. Older than 20 years of age
• • 4. Eastern Cooperative Oncology Group performance status of 0-2
• • 5. Patient is able to comply with scheduled visits, evaluation plans, and other study procedures
• • 6. Patient is willing to provide written informed consent
• Exclusion Criteria:
• • 1. Active or suspected cancer, or a history of malignancy where the risk of recurrence is equal or higher than 20% within 2 years.
• • 2. Significant medical comorbidities in which survival is predicted to be less than 3 years
• • 3. Estimated glomerular filtration rate \< 30 mL/min/1.73m²
• • 4. Patient not eligible for applying LI-RADS criteria, such as Budd-Chiari Syndrome
• • 5. Precautions for MRI (cardiac pacemaker, severe claustrophobia that may interfere with protocol compliance).
• • 6. Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with completing the study